SLC5A2 and stroke disorder: While reducing infarct size is not equal to reducing the risk of an ischemic event, it is notable that only the dual SGLT1/2 inhibitor sotagliflozin reduced the risk of myocardial infarction and stroke in patients with T2DM, but not selective SGLT2 inhibitors.